Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.
Peter Voorhees, MD, a myeloma specialist at Levine Cancer Institute, discusses the latest data for the use of pomalidomide (Pomalyst)-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.
There have been several randomized clinical trials that have demonstrated superiority of pomalidomide-based combinations, Voorhees says. The phase II ELOQUENT-3 trial, in particular, looked at the combination of pomalidomide plus dexamethasone with or without elotuzumab (Empliciti). Results showed that patients had a higher likelihood of responding to the 3-drug regimen as compared with the 2-drug combination, and the depth of response also improved with the addition of elotuzumab. This translated to a significant improvement in median progression-free survival (PFS).
These phase II data led to theFDA approval of elotuzumab in combination with pomalidomide and low-dose dexamethasonefor the treatment of patients with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapies.
In the randomized phase III ICARIA-MM trial, presented at the 2019 ASCO Annual Meeting,the triplet regimen of pomalidomide, dexamethasone, and isatuximab also led to similar findings
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More